Skip to content

13F-HR filed by Venrock Adviser, LLC

Venrock Adviser, LLC filed this 13F-HR for the quarter ended 2025-12-31, filed 2026-02-17, with 27 holding rows worth $2,024,517,832.

Accession
0001615982-26-000005
Filed
2026-02-17
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2025

A holdings report, 27 entries on the cover page, a total value of $2,024,517,832 stated on the cover page (in dollars after the unit check, H1), rows summing to $2,024,517,832 with VALUE read as dollars as filed, 13F file number 028-20281. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
APOGEE THERAPEUTICS INC COM03770N101Stock8,493,321$641,075,869dollars as filed
ORUKA THERAPEUTICS INC COM687604108Stock4,148,428$125,738,853dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM3,882,709$120,829,904dollars as filed
SPYRE THERAPEUTICS INC00773J202COM NEW3,685,448$120,735,276dollars as filed
KALVISTA PHARMACEUTICALS INC483497103COM6,728,985$108,673,108dollars as filed
OCULAR THERAPEUTIX INC67576A100COM7,315,547$88,810,741dollars as filed
SAVARA INC805111101COM13,740,375$82,854,461dollars as filed
COGENT BIOSCIENCES INC19240Q201COM2,000,000$71,040,000dollars as filed
ERASCA INC COM29479A108Stock17,857,083$66,428,349dollars as filed
CYTOMX THERAPEUTICS INC23284F105COMMON STOCK15,561,500$66,291,990dollars as filed
MAZE THERAPEUTICS INC COM578784100Stock1,548,569$64,157,214dollars as filed
JADE BIOSCIENCES INC008064206COM NEW3,220,364$49,690,217dollars as filed
ENLIVEN THERAPEUTICS INC COM29337E102Stock3,226,331$49,685,497dollars as filed
ORIC PHARMACEUTICALS INC68622P109COM5,676,230$46,431,561dollars as filed
ENGENE HOLDINGS INC29286M105COM4,771,414$43,085,868dollars as filed
DYNE THERAPEUTICS INC COM26818M108Stock2,173,913$42,521,738dollars as filed
DIANTHUS THERAPEUTICS INC252828108COM1,000,000$41,210,000dollars as filed
UPSTREAM BIO INC91678A107COMMON STOCK1,169,298$31,746,441dollars as filed
CYBIN INC23256X407COM NEW3,840,250$31,413,245dollars as filed
ZURA BIO LTDG9TY5A101COMMON STOCK5,345,115$28,008,403dollars as filed
VOR BIOPHARMA INC929033207COMMON STOCK1,943,766$25,424,459dollars as filed
CRESCENT BIOPHARMA INCG2545C104COMMON STOCK2,133,576$25,304,211dollars as filed
SEPTERNA INC COM81734D104Stock610,808$17,029,327dollars as filed
SURROZEN INC86889P208COMMON STOCK632,931$14,304,241dollars as filed
CULLINAN THERAPEUTICS INC230031106COM1,379,965$14,282,638dollars as filed
ARTIVA BIOTHERAPEUTICS INC04317A107COM1,609,569$6,905,051dollars as filed
CASI PHARMACEUTICALS INC COM NEWG1933S101Stock987,259$839,170dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001615982-26-000005this filing2026-02-17acceptance time not in the bulk data set